Further loading tumor antigens and adjuvants CpG ODN, GM-CSF into the blood clot scaffold stimulated the recruited immune cells into tumor antigen-specific immune cells, effectively inhibiting the growth of B16F10 and 4T1 tumor, establishing an effective personalized cancer vaccine. This evidence concerns the gene CSF2 and neoplasm.